Albert Pares

Summary

Affiliation: University of Barcelona
Country: Spain

Publications

  1. doi request reprint Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers
    Anna Cavazza
    Liver Unit, Digestive Diseases Institute, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Hepatology 50:1162-8. 2009
  2. ncbi request reprint Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial
    A Pares
    Hospital Clinic i Provincial, University of Barcelona, Spain
    J Hepatol 28:615-21. 1998
  3. ncbi request reprint Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver
    A Pares
    Liver Unit, Hospital Clinic, University of Barcelona, Spain
    J Hepatol 32:561-6. 2000
  4. ncbi request reprint [Prevalence and factors associated to the presence of fatty liver in apparently healthy adult men]
    A Pares
    Unidade de Alcohología, Hospital Clinic, Universidad de Barcelona
    Med Clin (Barc) 114:561-5. 2000
  5. ncbi request reprint Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis
    A Pares
    Liver and Metabolic Bone Diseases Units, Department of Rheumatology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Hepatology 33:554-60. 2001
  6. ncbi request reprint [Liver-assist non-biological artificial systems]
    A Pares
    Unidad de Hepatologia, Institut de Malalties Digestives, Hospital Clinic, Barcelona
    Gastroenterol Hepatol 25:43-7. 2002
  7. ncbi request reprint [Physiopathological bases for the treatment of acute alcoholic hepatitis]
    A Pares
    Unidad de Hepatologia, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, IDIBAPS, Barcelona, Espana
    Gastroenterol Hepatol 27:30-9. 2004
  8. ncbi request reprint Natural history of primary biliary cirrhosis
    Albert Pares
    Liver Unit, Institute of Digestive Diseases, Hospital Clinic, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    Clin Liver Dis 7:779-94. 2003
  9. doi request reprint The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts
    Anna Enjuanes
    Metabolic Bone Diseases Unit, Department of Rheumatology, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Endocrine 37:180-6. 2010
  10. ncbi request reprint Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells
    Marta Dubreuil
    Centro de Investigación Biomédica en Red, University of Barcelona, Barcelona, Spain
    Liver Int 33:1029-38. 2013

Detail Information

Publications35

  1. doi request reprint Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers
    Anna Cavazza
    Liver Unit, Digestive Diseases Institute, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Hepatology 50:1162-8. 2009
    ..38, P < 0.001). When analyzing the two series separately, male gender was associated with higher likelihood of HCC in Padova (OR: 8.09, 95% CI: 1.93-33.8, P < 0.01). The median survival after the diagnosis of HCC was 36 months...
  2. ncbi request reprint Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial
    A Pares
    Hospital Clinic i Provincial, University of Barcelona, Spain
    J Hepatol 28:615-21. 1998
    ..Therefore, this study was carried out to determine the effect of silymarin in alcoholics with liver cirrhosis with respect to survival and clinical and laboratory changes...
  3. ncbi request reprint Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver
    A Pares
    Liver Unit, Hospital Clinic, University of Barcelona, Spain
    J Hepatol 32:561-6. 2000
    ..The aim of this study was to assess the efficacy of ursodeoxycholic acid (UDCA) for primary biliary cirrhosis in a randomized, double-blind placebo-controlled trial...
  4. ncbi request reprint [Prevalence and factors associated to the presence of fatty liver in apparently healthy adult men]
    A Pares
    Unidade de Alcohología, Hospital Clinic, Universidad de Barcelona
    Med Clin (Barc) 114:561-5. 2000
    ..Therefore the aim of this study was to assess the prevalence and associated factors for fatty liver diagnosed by ultrasonography...
  5. ncbi request reprint Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis
    A Pares
    Liver and Metabolic Bone Diseases Units, Department of Rheumatology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Hepatology 33:554-60. 2001
    ..In conclusion, the COLIA1 but not VDR polymorphism is a genetic marker of peak bone mass in patients with PBC, although the severity of cholestasis is the main factor for osteoporosis since it is associated with the rate of bone loss...
  6. ncbi request reprint [Liver-assist non-biological artificial systems]
    A Pares
    Unidad de Hepatologia, Institut de Malalties Digestives, Hospital Clinic, Barcelona
    Gastroenterol Hepatol 25:43-7. 2002
  7. ncbi request reprint [Physiopathological bases for the treatment of acute alcoholic hepatitis]
    A Pares
    Unidad de Hepatologia, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, IDIBAPS, Barcelona, Espana
    Gastroenterol Hepatol 27:30-9. 2004
  8. ncbi request reprint Natural history of primary biliary cirrhosis
    Albert Pares
    Liver Unit, Institute of Digestive Diseases, Hospital Clinic, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    Clin Liver Dis 7:779-94. 2003
    ..Prognostic models based on serial measurements of the independent predictors of poor prognosis would lead to a more accurate prediction of survival; however, they probably will not replace clinical outlook...
  9. doi request reprint The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts
    Anna Enjuanes
    Metabolic Bone Diseases Unit, Department of Rheumatology, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Endocrine 37:180-6. 2010
    ..Thus, we conclude that alendronate does not affect the ALP activity and OPG gene expression in differentiated hOB, but may increase RANKL gene expression induced by vitamin D...
  10. ncbi request reprint Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells
    Marta Dubreuil
    Centro de Investigación Biomédica en Red, University of Barcelona, Barcelona, Spain
    Liver Int 33:1029-38. 2013
    ..Lithocholic acid (LCA) and bilirubin may play a role in osteoporosis given that both substances have detrimental effects on survival of human osteoblasts, the cells involved in bone formation...
  11. ncbi request reprint Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis
    Nuria Guanabens
    Metabolic Bone Diseases Unit, Hospital Clinic, Institut d Investigacions Mèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Am J Gastroenterol 98:2268-74. 2003
    ..In this study, we have compared two bisphosphonates, alendronate and cyclical etidronate, that inhibit osteoclast-mediated bone resorption and have examined their effects on bone mass in patients with this disease...
  12. ncbi request reprint Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis
    Nuria Guanabens
    Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Gastroenterology 138:2348-56. 2010
    ..We studied a large series of women with PBC to assess the prevalence and risk factors for fractures and the fracture threshold...
  13. doi request reprint Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases
    Silvia Ruiz-Gaspa
    Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas CIBEREHD, Institut d Investigacions Biome diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Hepatology 54:2104-13. 2011
    ..These results support the deleterious consequences of increased bilirubin in advanced chronic cholestasis and in end-stage liver diseases, resulting in disturbed bone formation related to osteoblast dysfunction...
  14. doi request reprint Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis
    Nuria Guanabens
    Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CIBERehd, Barcelona, Spain
    Hepatology 58:2070-8. 2013
    ..Adherence to therapy was higher with ibandronate (P = 0.009). Neither treatment impaired liver function or cholestasis...
  15. doi request reprint [Osteoporosis in liver cirrhosis]
    Nuria Guanabens
    Servicio de Reumatologia, Unidad de Hepatologia, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Insititut d Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic, Universidad de Barcelona, Espana
    Gastroenterol Hepatol 35:411-20. 2012
    ..There are no specific recommendations on drug treatment but bisphosphonates are effective in increasing bone mass in patients with chronic cholestasis and have a good safety profile...
  16. ncbi request reprint Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis
    Albert Pares
    Liver Unit, Institut Clinic de Malalties Digestives, Hospital Clinic, Barcelona, Spain
    Am J Gastroenterol 99:1105-10. 2004
    ....
  17. ncbi request reprint Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis
    Nuria Guanabens
    Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clinic, IDIBAPS, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 42:573-7. 2005
    ..Since primary biliary cirrhosis (PBC) is usually diagnosed in postmenopausal women with minor cholestasis, it has been questioned whether PBC itself represents a further risk for osteoporosis...
  18. ncbi request reprint Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome
    Manuel Ramos-Casals
    Department of Autoimmune Diseases and Hepatology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, IDIBAPS, School of Medicine, University of Barcelona, Barcelona, Spain
    J Rheumatol 33:1593-9. 2006
    ..To analyze the prevalence and clinical significance of liver involvement in patients with Sjögren's syndrome (SS), focusing on the characterization and differentiation of autoimmune versus chronic viral liver disease...
  19. doi request reprint The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts
    Anna Enjuanes
    Metabolic Bone Diseases Unit, Department of Rheumatology, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Endocrine 37:322-8. 2010
    ..Thus, we conclude that alendronate does not affect the ALP activity and OPG gene expression in differentiated hOB, but may increase RANKL gene expression induced by vitamin D...
  20. doi request reprint High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue
    Nuria Guanabens
    Metabolic Bone Diseases Unit, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, IDIBAPS, University of Barcelona, Barcelona, Spain
    J Bone Miner Metab 27:347-54. 2009
    ..In conclusion, osteoprotegerin and RANKL are abnormal in patients with PBC, regardless of osteoporosis. The elevated circulating osteoprotegerin is associated with the severity of disease, but not with gene expression in the liver...
  21. doi request reprint Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers
    Albert Pares
    Liver Unit, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain
    J Hepatol 53:307-12. 2010
    ..Therefore, we analyzed patients with resistant pruritus treated with MARS from three centers, to assess the changes on pruritus and the indices of cholestasis...
  22. ncbi request reprint Prevalence and mechanisms of hyperhomocysteinemia in chronic alcoholics
    Carmen Blasco
    Liver Unit, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Alcohol Clin Exp Res 29:1044-8. 2005
    ..The aim of the study was to investigate the prevalence of hyperhomocysteinemia in chronic alcoholics and the influence of alcohol consumption, vitamin deficiencies and liver damage on the plasma levels of Hcy...
  23. ncbi request reprint Expected developments in hepatology
    Xavier Forns
    Liver Unit, Hospital Clinic, Institut d Investigaciones Biomèdiques August Pi i Sunyer, University of Barcelona, Spain
    Best Pract Res Clin Gastroenterol 16:957-70. 2002
    ..The risk factors and primary, secondary and tertiary prevention of the condition are also analysed. Finally, the development of new therapeutic strategies for hepatocellular carcinoma is evaluated by evidence-based studies...
  24. ncbi request reprint Treatment of bone disorders in liver disease
    Albert Pares
    Liver Unit, Digestive Diseases Institute and Metabolic Bone Diseases Unit, Department of Rheumatology Hospital Clínic, IDIBAPS, Barcelona, Spain
    J Hepatol 45:445-53. 2006
  25. doi request reprint Management of osteoporosis in liver disease
    Nuria Guanabens
    Liver Unit, Department of Rheumatology, Hospital Clinic, CIBERHED, University of Barcelona, Barcelona, Spain
    Clin Res Hepatol Gastroenterol 35:438-45. 2011
    ..Randomized studies assessing bisphosphonates in larger series of patients, the development of new drugs for osteoporosis and the improvement in the management of liver transplant recipients may change the future...
  26. ncbi request reprint Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid
    Albert Pares
    Liver Unit, Digestive Diseases Institute, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Gastroenterology 130:715-20. 2006
    ....
  27. ncbi request reprint Serum immunological profile in patients with chronic autoimmune cholestasis
    Manuel Romero-Gomez
    Unidad de Hepatologia, Hospital Universitario de Valme, Sevilla, Spain
    Am J Gastroenterol 99:2150-7. 2004
    ..To compare patients who had biochemical and histological features of chronic autoimmune cholestasis (CAIC) using serological autoantibody profiling...
  28. doi request reprint Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment
    Albert Pares
    Liver Unit, Institute of Digestive Diseases, Hospital Clinic, Institut d Investigacions Biomèdiques August Pi Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain
    Clin Liver Dis 12:407-24; x. 2008
    ..The potential usefulness of new agents requires further evaluation...
  29. ncbi request reprint Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis
    Albert Pares
    Liver Unit, Hospital Clinic, University of Barcelona, Spain
    Eur J Gastroenterol Hepatol 17:311-5. 2005
    ..These features may exceed the potential effect of gene polymorphisms on osteoporosis in PBC...
  30. pmc Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease
    Cristián Cerda
    Liver Unit, Institute of Digestive and Metabolic Diseases, Hospital Clinic, 08036 Barcelona, Spain
    World J Gastroenterol 19:5381-4. 2013
    ....
  31. doi request reprint Liver and bone
    Nuria Guanabens
    Department of Rheumatology, University of Barcelona, Barcelona, Spain
    Arch Biochem Biophys 503:84-94. 2010
    ..Randomized studies assessing bisphosphonates in larger series of patients, the development of new drugs for osteoporosis and the improvement in the management of liver transplant recipients may change the future...
  32. pmc Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure
    Albert Pares
    Liver Unit, Digestive Diseases Institute, Hospital Clinic, Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Crit Care 13:R8. 2009
    ..The aim of this study was to assess the effects of albumin dialysis on hepatic encephalopathy and circulating levels of amino acids in severe alcoholic hepatitis...
  33. ncbi request reprint [Natural history of primary biliary cirrhosis]
    Albert Pares
    Unidad de Hepatologia, Institut Clinic de Malalties Digestives i Metaboliques, Hospital Clinic, IDIBAPS, Barcelona, Espana
    Gastroenterol Hepatol 31:500-7. 2008
    ..There are distinct mathematical prognostic models that sensitively predict the probability of survival and are useful to determine disease severity in specific patients...
  34. doi request reprint Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid
    Sabela Lens
    Liver Unit, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain
    Liver Int 34:197-203. 2014
    ..Since potential favourable effects of fibrates have been reported in short series with inconclusive results, we have carried out a pilot study to analyse the effects of bezafibrate in patients with suboptimal response to UDCA...
  35. doi request reprint Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial
    Rafael Bañares
    Liver Unit, Hospital General Universitario Gregorio Maranon, IISGM, Medical School, Universidad Complutense, Madrid, Spain
    Hepatology 57:1153-62. 2013
    ..02) and bilirubin (P=0.001) and a more frequent improvement in HE (from grade II-IV to grade 0-I; 62.5% versus 38.2%; P=0.07) was observed in the MARS group. Severe adverse events were similar...